

Nemo: Next Generation Therapy for Skin Diseases

PRINCIPLE INVESTIGATOR:
Prof. Dr. Sarah Hedtrich
BIH/Charité



SUMMARY

Genodermatoses are rare hereditary skin diseases characterized by impaired skin barrier function. This leads to increased transepidermal water loss and high risk for infection which is particularly dangerous for neonates causing higher mortality rates. In general, patient's quality of life and life expectancy are severely affected. Currently no effective and curative treatments exist. Symptomatic treatments include frequent (2x/day) and rigorous bathing to remove affected skin areas followed by the application of moisturizers. These treatments are very time consuming, costly and might not be covered by health insurances. The team develops a topically applicable gene therapy as novel and potentially curative treatment option for genodermatoses. If the approach proves successful, the market will be broadened by targeting common skin diseases.

PROJECT GOALS

- Optimization of intradermal delivery
- Proof-of-concept study in a skin disease model
- Preclinical safety study

LONG-TERM GOALS

- Formation of spin-off company